secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2026-08-11T20:11:16+00:00
Accession:  0001193125-26-344645
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology Q2 2026: positive Phase 2 mCRC data, FDA aligned on Phase 3, licensing dispute
--------------------------------------------------------------------------------

- Q2 2026 cash ~$34.5M; six-month net cash burn $24.1M vs $21.1M in 2025; runway into Q3 2027
- Phase 2 CRDF-004: 30mg onvansertib+FOLFIRI/bev confirmed ORR 72.2% vs 42.1% for SoC; PFS HR 0.55 (BICR)
- Completed FDA End-of-Phase 2 meeting; aligned on Phase 3 design; initiation planned Q1 2027 subject to financing
- Completed $10M registered direct offering in July 2026 to extend cash runway
- Licensor NMS alleged material breach and terminated license; Cardiff filed lawsuit in May 2026 seeking declaratory relief

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/0001193125-26-344645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/crdf-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-344645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer